Skip to main content
logo
Veraxa Biotech AG (VRXA)
NASDAQ: VRXA · Real-Time Price · USD
1.530
-0.110 (-6.71%)
Aug 27, 2026, 9:59 AM EDT - Market open

Veraxa Biotech AG Cash Flow Statement

Millions CHF. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Net Income
-28.13-16.54
Depreciation & Amortization
1.871.84
Other Amortization
0.010.01
Loss (Gain) From Sale of Assets
0.03-
Stock-Based Compensation
18.337.61
Other Operating Activities
-0.260.51
Change in Accounts Payable
-0.12-0.36
Change in Other Net Operating Assets
0.560.53
Operating Cash Flow
-7.72-7.27
Operating Cash Flow Growth
--

Investing Activities

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Capital Expenditures
-0.12-0.23
Cash Acquisitions
--0.78
Investing Cash Flow
-0.12-1.02

Financing Activities

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Issuance of Common Stock
1.8512.54
Financing Cash Flow
1.8512.54

Net Cash Flow

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Net Cash Flow
-5.994.25

Free Cash Flow

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Free Cash Flow
-7.84-7.5
Free Cash Flow Growth
--
Free Cash Flow Per Share
-0.56-0.55
Levered Free Cash Flow
3.07-
Unlevered Free Cash Flow
3.07-

Additional Metrics

Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Change in Working Capital
0.44-0.69
SEC Filings: 10-K · 10-Q